Cell, Gene, and RNA Therapies are shifting the aim of drug development from managing symptoms to delivering durable, potentially curative therapies. But moving a construct from a promising preclinical milestone to a viable commercial asset—whether an ex vivo cell therapy, an in vivo viral vector, or an RNA platform such as an ASO, or an siRNAs—is often more operationally challenging than anything in conventional development. For these modalities, a protocol can’t only be built... The post Patient-Centered Execution Across Cell, Gene, and RNA Therapeutics appeared first on Premier Research .
Patient-Centered Execution Across Cell, Gene, and RNA Therapeutics
Kenneth Ndugga-Kabuye